

PROGRAM

8:15 am - 9:00 am

Registration & Welcome coffee

9:00 am - 9:10 am

Opening remarks

- **Marc BONNEVILLE**, Chairman of ARIIS & **Yves LEVY**, Chairman of Aviesan

9:10 am - 9:30 am

21st century epidemiology: challenges and opportunities

- **Gilles BABINET**, France's Digital Champion for the European Commission

9:30 am - 9:50 am

The "Constances" cohort: design, purpose and foresight

- **Marie ZINS**, Principal Investigator of Constances - Professor of Epidemiology, Paris Descartes University, Inserm UMS 11



9:50 am - 10:45 am

Round table 1 - AI for biomarker discovery: what can we truly expect?

- **Stanley DURLEMAN**, Co-Head, INRIA/ICM Brain and Spine Institute, ARAMIS Lab
- **Xosé FERNANDEZ**, Chief Data Officer, Curie Institute
- **Meriem SEFTA**, Partnership and Translational Research Manager, Owkin
- **Benoit TYL**, Director of Cardiovascular Translational Research, Servier
- **Nicolas VILLAIN**, Head of Research in AI for Medical Imaging, Philips



10:45 am - 11:00 am

Practical case - From Paris to Boston: a "deep patient" in nephrology

- **Alexandre LOUPY**, Nephrologist, Necker Hospital, Paris Descartes University and Assistance Publique-Hôpitaux de Paris Inserm U970

11:00 am - 11:30 am

Coffee break - Networking

11:30 am - 11:50 am

An insight by a global industry - Human derived genome scale data sets and advanced analytics to accelerate drug discovery

- **Philippe SANSEAU**, Head Computational Biology and Stats, GSK (United Kingdom)

11:50 am - 12:45 pm

Round table 2 - Real-world data: foresight on tomorrow's gold standard

- **Michèle ARNOE**, Head Growth and Innovation, IQVIA
- **Stéphanie COMBES**, Head of the health data administration mission, DREES
- **Marc FROUIN**, Chief Operating Officer, BioSerenity
- **Ramon HERNANDEZ**, Head of Advanced Analytics in R&D, Sanofi
- **Remy SLAMA**, SEPAGES cohort, Inserm U1209 Grenoble Alpes University, CNRS UMR5309



12:45 pm - 12:55 pm

Overview of the rising French start-ups using AI on Cohorts

- **Rosalie MAURISSE**, Head of the health sector, Expertise Direction, BpiFrance



12:55 pm - 1:15 pm

Concluding remarks and insight from Israel

- **Ran BALICER**, Founding Director, Clalit Research Institute (Israel)

1:15 pm - 2:30 pm

Lunch & Networking with start-ups



Presentation in French: headphones available for simultaneous English translation

Special thanks to:



STATION F



B2B Meetings [PRIVATE ACCESS - By invitation only]

The B2B meetings are dedicated to cohorts and industries with the aim to develop new public/private partnerships. 16 cohorts and 14 industrial delegations will take part in these meetings:

Cohorts:

- ❖ **BACAP** - Adenocarcinoma Pancreatic Cancer
- ❖ **CANTO** - Breast Cancer
- ❖ **CKD-REIN** - Chronic Kidney Disease
- ❖ **COBLAnCE** - Bladder Cancer
- ❖ **Colibri** - Obstructive lung diseases and interstitial lung diseases
- ❖ **Constances** - General population
- ❖ **Elfe** - Cohort of children
- ❖ **Epipage2** - Cohort of premature
- ❖ **ESME** - Metastatic breast cancer, ovarian cancer and advanced metastatic lung cancer
- ❖ **E3N/E4N** - Multi-generational cohort
- ❖ **FREGAT** - Oesophago-gastric cancers
- ❖ **MEMENTO** - Alzheimer's disease
- ❖ **OFSEP** - Multiple sclerosis
- ❖ **RAMSES** - Multiple sclerosis
- ❖ **REALYSA** - Lymphoma
- ❖ **SFDT1** - Diabetes type 1

Industries:

- ❖ **ASTRAZENECA**
- ❖ **GSK**
- ❖ **IPSEN**
- ❖ **IQVIA**
- ❖ **JANSSEN**
- ❖ **LILLY**
- ❖ **MERCK**
- ❖ **MSD**
- ❖ **PFIZER**
- ❖ **ROCHE**
- ❖ **SANOFI PASTEUR**
- ❖ **SERVIER**
- ❖ **SHIRE**
- ❖ **STAGO**